Theravance Biopharma to Present New Data Highlighting Potent in vitro Activity of VIBATIV (telavancin) Against Difficult-to-Treat, Clinical Pathogens, Including MRSA, at ASM Microbe 2016 Conference
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|TBPH||Community voting in process|
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?